A new case report published in Cureus documents atypical fibroxanthoma (AFX) containing osteoclast-like giant cells — a histopathological pattern rare enough that the authors paired their single-case findings with a full review of the literature.

Atypical fibroxanthoma is a low-grade malignant cutaneous neoplasm of fibrohistiocytic origin. It typically arises on sun-damaged skin of the head and neck in older patients. Standard histology shows pleomorphic spindle cells, atypical multinucleated giant cells and lipidized areas. The osteoclast-like giant cell variant alters that familiar picture enough to create real diagnostic risk: bland osteoclast-like cells can be mistaken for a reactive process or for another giant cell-rich tumor, including malignant melanoma and poorly differentiated squamous cell carcinoma.

Why does this variant matter to dermatopathology?

Diagnostic accuracy drives management. AFX is generally treated with wide local excision or Mohs micrographic surgery, and it carries a favorable prognosis when completely excised. Misreading a giant cell-rich lesion can push clinicians toward the wrong workup — sentinel node evaluation, wider margins or adjuvant therapy — for a tumor that usually behaves indolently.

The authors frame their case as a contribution to a small published literature on this entity, using their review to consolidate what is known about its morphology and its differential diagnosis.

What should pathologists watch for?

The report's core teaching point concerns recognition:

• Osteoclast-like giant cells are uniformly bland, in contrast to the pleomorphic, atypical multinucleated giant cells of conventional AFX.
• Their presence does not, by itself, exclude atypical fibroxanthoma.
• Immunohistochemistry remains central to confirming fibrohistiocytic lineage and excluding mimics such as melanoma and carcinoma.

How does the paper position itself?

As a report of a rare histopathological entity, the article combines the authors' own case observations with a structured review of prior publications. This format lets the authors define the diagnostic features of AFX with osteoclast-like giant cells more precisely than a single case description would allow.

The authors conclude that awareness of this variant should help dermatopathologists avoid diagnostic error when they encounter giant cell-rich dermal tumors in elderly, sun-exposed patients. Whether the variant carries any distinct clinical behavior remains a question the existing literature is too small to settle — a gap the authors' review helps delineate for future case documentation.